Fig. 2.
Correlation of FB50 immunostaining with survival in patients with squamous cell carcinoma (A), large cell (B), and adenocarcinoma (C).
Correlation of FB50 immunostaining with survival in patients with squamous cell carcinoma (A), large cell (B), and adenocarcinoma (C).